ArticleJournal of cancer research and clinical oncology2026
Breast cancer prevention in patients with gBRCA-mutated ovarian cancer.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOvarian cancer is frequently associated with gBRCA1/2 mutations, which also confer a high lifetime risk of breast cancer in non-affected patients. While risk-reducing salpingo-oophorectomy (RRSO) is established in hereditary breast and ovarian cancer prevention, the recommendation for risk-reducing bilateral mastectomy (RRBM) remains unclear in gBRCA1/2mutovarian cancer patients due to high recurrence rates and limited survival. This study evaluates the preventive strategies of these patients in a real-world setting.
methodsThis retrospective study included 49 patients with gBRCA1/2mut HGSC treated at the Hereditary Breast and Ovarian Cancer Centre, University Hospital Erlangen, between 2012 and 2024. Clinical, pathological, treatment-related, and genetic data were collected and analyzed from electronic records.
resultsAmong 49 patients with gBRCAmut HGSC, 44 out of 49 did not undergo a RRBM during follow-up. Intensified breast cancer surveillance was recommended to 33 patients. Although 19 out of 49 patients were formally recommended a RRBM, only two proceeded with the preventive option. Three additional patients chose the surgery driven by the diagnosis of metachronous breast cancer. 80% of the operations occurred > 60 months after ovarian cancer diagnosis.
conclusionsIn patients with gBRCA1/2mut and a history of HGSC, RRBM is rarely chosen. Most patients prefer an intensified surveillance program. Due to low metachronous breast cancer rate in follow up care, RRBM seems to be an option just for long-term survivors. Individual patient preferences play a crucial role in the management strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.